MacroGenics loses CMO Jon Wigginton as commercialization looms
The next few months are important for MacroGenics. They may soon have their first approved drug. They could even defeat mountainous odds and eclipse Keytruda …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
